Ocata Therapeutics Inc fka OCAT

[louisa]

West Coast (GP) are speculating on this...JV, FWIW, killing time here while Waiting for Godot. AIMO
From what I gather Ceasar has the ear to the God horn on this science. I could be way off base here as I usually am. Lanza now has the 2011 CELLebrity Calendar on his personal blog. Still laughing over this, great idea and hope it raises $$$'s and awareness. I have a slight crush on one of these guys. ROFL.

JV Potential
Inbox
X
Reply
Ceasar de Cuenca to Advanced
show details 11:47 AM (5 minutes ago)
The two more agressive BioPharma in the World of Stem Cells are Pfizer and Roche (Genentech).

Pfizer have formalized its Stem Cell Policy and have searched for Stem Cell Partners under their Biologics Division.

http://www.pfizer.com/research/research_clinical_trials/stem_cell_research.jsp

http://www.pfizer.com/research/partnering/partnering_with_pfizer.jsp

Genentech is the sub of Roche who undertakes most of the direct stem cell partnerships, while Roche handle the instrumentation including Assays.

Novartis is very active in the Blood Transfusion arena and is a competitor of Roche in this market segment relative to Blood Assays
and diagnostics specially in the HIV, Hepatitis, and Dengue. Both Roche and Novartis compete around the world in this market worth billions of dollars. A Universal Blood Filing by ACTC/CHA will have a major impart on Roche's and Novartis' Diagnostics Division, and it is to both of this companies interest to start talking to ACTC. Blood Banking and the US Red Cross and other Red Cross' around the globe will be decimated by the Hospital Industry and the Military will be overjoyed by this development.

The FDA would love this development because they will have eliminated one of the major causes of blood related transmission of infectious agents and deseases.

Cuenca